Wall Street analysts expect Arbutus Biopharma Corp (NASDAQ:ABUS) to post earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arbutus Biopharma’s earnings. Arbutus Biopharma posted earnings of ($0.90) per share during the same quarter last year, which suggests a positive year over year growth rate of 56.7%. The firm is scheduled to announce its next earnings results on Wednesday, March 13th.
According to Zacks, analysts expect that Arbutus Biopharma will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.30) to ($1.23). For the next fiscal year, analysts expect that the company will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.80) to ($1.57). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Arbutus Biopharma.
Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.13). The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $0.23 million. Arbutus Biopharma had a negative return on equity of 91.36% and a negative net margin of 1,116.69%.
A number of brokerages have commented on ABUS. Wedbush upped their price objective on shares of Arbutus Biopharma from $6.00 to $7.00 and gave the stock a “hold” rating in a research report on Monday, August 13th. Chardan Capital cut their price objective on shares of Arbutus Biopharma from $12.00 to $6.50 and set a “buy” rating for the company in a research report on Friday, October 12th. ValuEngine downgraded shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, December 1st. B. Riley upped their price objective on shares of Arbutus Biopharma from $9.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, August 13th. Finally, BidaskClub downgraded shares of Arbutus Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Arbutus Biopharma presently has a consensus rating of “Hold” and a consensus target price of $6.38.
Arbutus Biopharma stock traded down $0.18 during trading hours on Friday, reaching $4.40. 2,682 shares of the stock were exchanged, compared to its average volume of 196,412. The company has a market cap of $251.31 million, a P/E ratio of -2.47 and a beta of 1.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.38 and a current ratio of 11.38. Arbutus Biopharma has a 52-week low of $4.01 and a 52-week high of $12.60.
Several large investors have recently bought and sold shares of ABUS. Algert Global LLC acquired a new position in shares of Arbutus Biopharma during the 2nd quarter worth $254,000. Rhumbline Advisers purchased a new position in shares of Arbutus Biopharma during the 2nd quarter worth about $243,000. Bank of New York Mellon Corp purchased a new position in shares of Arbutus Biopharma during the 2nd quarter worth about $609,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Arbutus Biopharma during the 2nd quarter worth about $482,000. Finally, BlackRock Inc. lifted its holdings in shares of Arbutus Biopharma by 246.6% during the 2nd quarter. BlackRock Inc. now owns 2,391,143 shares of the biopharmaceutical company’s stock worth $17,455,000 after acquiring an additional 1,701,237 shares during the period. 42.59% of the stock is currently owned by institutional investors and hedge funds.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Featured Story: Cost of Equity For A Business, Investors
Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.